Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Boehringer Ingelheim
Chinese Patent Office
Deloitte
Julphar
Accenture
Cantor Fitzgerald
Chubb
Argus Health

Generated: December 9, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GADOTERATE MEGLUMINE

« Back to Dashboard

Clinical Trials for Gadoterate Meglumine

Trial ID Title Status Sponsor Phase Summary
NCT00650845 Renal Safety Evaluation After Dotarem®-Enhanced MRI Completed Guerbet Phase 4 Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial. The aim of this study was to evaluate the safety profile of gadoterate meglumine (Dotarem®) in patients with chronic renal insufficiency by evaluating the rate of patients experiencing contrast-induced nephrotoxicity following the injection of gadoterate meglumine.
NCT01010932 Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) Completed Guerbet Phase 3 The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
NCT01012674 Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) Completed Guerbet Phase 3 The study will evaluate the efficacy and safety of Dotarem enhanced MRA in patients suffering from carotid or vertebral arterial disease.
NCT01449266 Safety and Dialysability of Dotarem® in Dialysed Patients Completed Guerbet Phase 1 To evaluate the dialysability of Dotarem®, after an IV injection of 0.1 mmol/kg in patients with chronic renal failure who require hemodialysis treatment.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Gadoterate Meglumine

Condition Name

Condition Name for Gadoterate Meglumine
Intervention Trials
Cerebral Arterial Diseases 2
Breast Cancer Female 1
Renal Insufficiency 1
Magnetic Resonance Imaging 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Gadoterate Meglumine
Intervention Trials
Cerebral Arterial Diseases 2
Renal Insufficiency 2
Cardiomyopathies 1
Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Gadoterate Meglumine

Trials by Country

Trials by Country for Gadoterate Meglumine
Location Trials
United States 3
France 2
Belgium 2
Italy 1
Austria 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Gadoterate Meglumine
Location Trials
Indiana 2
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Gadoterate Meglumine

Clinical Trial Phase

Clinical Trial Phase for Gadoterate Meglumine
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Gadoterate Meglumine
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Gadoterate Meglumine

Sponsor Name

Sponsor Name for Gadoterate Meglumine
Sponsor Trials
Guerbet 5
Boston Medical Center 1
University of Campinas, Brazil 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Gadoterate Meglumine
Sponsor Trials
Industry 5
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
Federal Trade Commission
Accenture
Farmers Insurance
McKinsey
QuintilesIMS
Baxter
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.